Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)
- PMID: 26999019
- PMCID: PMC4801414
- DOI: 10.1371/journal.pone.0152341
Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)
Erratum for
-
Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).PLoS One. 2015 Dec 23;10(12):e0145468. doi: 10.1371/journal.pone.0145468. eCollection 2015. PLoS One. 2015. PMID: 26698858 Free PMC article. Clinical Trial.
References
-
- Izumi K, Kaneko Y, Hashizume M, Yoshimoto K, Takeuchi T (2015) Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PLoS ONE 10(12): e0145468 doi:10.1371/journal.pone.0145468 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
